Spectrum Pharma

Spectrum Pharmaceuticals, Inc. is a biotechnology company, which engages in the acquisition, development and commercialization of a pipeline of novel and targeted oncology therapies. Its product pipeline includes: Eflapegrastim, Poziotinib, and IGN002. The company was founded in December 1987 and is headquartered in Henderson, NV.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Spectrum Pharmaceuticals, Inc. is a biotechnology company, which engages in the acquisition, development and commercialization of a pipeline of novel and targeted oncology therapies. Its product pipeline includes: Eflapegrastim, Poziotinib, and IGN002. The company was founded in December 1987 and is headquartered in Boston, MA.

SAN DIEGO, Aug. 6, 2021 /PRNewswire/ -- Shareholder rights law firm Johnson Fistel, LLP is investigating potential violations of the federal securities laws by Spectrum Pharmaceuticals, Inc. ("Spectrum" or the "Company") (NASDAQ: SPPI). On August 6, 2021, Spectrum announced the Company received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration regarding the Company's Biologics License Application for ROLONTIS®.

(SPPI) Alert: Did You Lose Money on Your Investment? Contact Johnson Fistel Regarding Investigation

The company received a thumbs-down from the FDA for its lead pipeline candidate.

Why Spectrum Pharmaceuticals Stock Is Crashing Today

Boston, Massachusetts--(Newsfile Corp. - August 6, 2021) - Block & Leviton is investigating Spectrum Pharmaceuticals, Inc. (NASDAQ: SPPI) for potential securities law violations. Investors who have lost money in their Spectrum Pharmaceuticals investment should contact the firm to learn more about how they might recover those losses. For more details, visit https://www.blockleviton.com/cases/sppi.What is this all about?Spectrum announced today that the Company received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration regarding...

SPECTRUM PHARMACEUTICALS INVESTIGATION: Block & Leviton Is Investigating Spectrum Pharmaceuticals For Potential Securities Law Violations; Investors Who Have Lost Money Are Encouraged to Contact the Firm

Spectrum Pharmaceuticals Inc (NASDAQ: SPPI) has received an FDA Complete Response Letter (CRL) regarding its marketing application for Rolontis (eflapegrastim) for neutropenia (low count of a type of white blood cell) in patients receiving myelosuppressive anti-cancer drugs. The CRL cited deficiencies related to manufacturing and indicated that a reinspection would be necessary.

Spectrum Pharma Stock Craters As FDA Slaps Response Letter For Its Neutropenia Candidate

HENDERSON, Nev.--(BUSINESS WIRE)---- $SPPI--Spectrum Pharmaceuticals (NasdaqGS: SPPI), today announced receipt of a CRL from the U.S. FDA regarding its BLA for ROLONTIS® (eflapegrastim).

Spectrum Pharmaceuticals Receives Complete Response Letter from FDA for ROLONTIS® (eflapegrastim)

HENDERSON, Nev.--(BUSINESS WIRE)---- $SPPI--Spectrum Pharmaceuticals (SPPI), will host a conf. call to discuss 2Q 2021 financial results and provide a corp update on 8.12.21 at 4:30 p.m. ET.

Spectrum Pharmaceuticals to Report Second Quarter 2021 Financial Results and Provide Corporate Update

The FDA completed the inspection of Hanmi's Korean facility almost a month ago.

Spectrum's Big Approval: Any Day Now

Investors need to pay close attention to for Spectrum Pharmaceuticals (SPPI) stock based on the movements in the options market lately.

Implied Volatility Surging for Spectrum Pharmaceuticals (SPPI) Stock Options

HENDERSON, Nev.--(BUSINESS WIRE)---- $SPPI--Spectrum Pharmaceuticals today presented an e-poster on poziotinib CNS activity in patients with NSCLC EGFR or HER2 exon 20 mutations at ASCO.

Spectrum Pharmaceuticals Presents Poziotinib Data in Patients with Brain Metastases from the ZENITH20 Clinical Trial at 2021 ASCO Annual Meeting

HENDERSON, Nev.--(BUSINESS WIRE)---- $SPPI--Spectrum Pharmaceuticals announces that the FDA is “on site” for the ROLONTIS® (eflapegrastim) manufacturing facility inspection.

Spectrum Pharmaceuticals Announces That the ROLONTIS® (eflapegrastim) Pre-Approval Inspection Has Been Initiated

HENDERSON, Nev.--(BUSINESS WIRE)---- $SPPI--Spectrum Pharmaceuticals to present poster for poziotinib in brain mets at upcoming ASCO Annual Meeting beginning on June 4 2021.

Spectrum Pharmaceuticals to Present Data for Poziotinib in Patients with Brain Metastases at the Upcoming 2021 ASCO Annual Meeting

HENDERSON, Nev.--(BUSINESS WIRE)---- $SPPI--Spectrum Pharmaceuticals (SPPI) to participate in the Jefferies and JMP Securities investor conferences in June.

Spectrum Pharmaceuticals to Participate in Two Upcoming Investor Conferences in June

Rolontis approval was delayed due to Covid-19 and the FDA's inability to inspect its Korean manufacturing facility. The FDA plans to inspect the Hanmi facility this month.

Spectrum Pharmaceuticals: Rolontis Korean Facility Inspection Presents Opportunity

Spectrum Pharmaceuticals, Inc. (SPPI) CEO Joe Turgeon on Q1 2021 Results - Earnings Call Transcript

HENDERSON, Nev.--(BUSINESS WIRE)---- $SPPI--Spectrum Pharmaceuticals Reports First Quarter 2021 Financial Results and Corporate Update

Spectrum Pharmaceuticals Reports First Quarter 2021 Financial Results and Corporate Update

HENDERSON, Nev.--(BUSINESS WIRE)---- $sppi--Spectrum Pharmaceuticals to Report First Quarter 2021 Financial Results and Provide Corporate Update

Spectrum Pharmaceuticals to Report First Quarter 2021 Financial Results and Provide Corporate Update

HENDERSON, Nev.--(BUSINESS WIRE)---- $SPPI #AACR--Spectrum Pharmaceuticals Presents Additional Twice Daily Dosing Data for Poziotinib at the AACR Virtual Meeting 2021

Spectrum Pharmaceuticals Presents Additional Twice Daily Dosing Data for Poziotinib at the AACR Virtual Meeting 2021

HENDERSON, Nev.--(BUSINESS WIRE)---- $SPPI #AACR--Spectrum Pharmaceuticals Presentations at the Upcoming AACR Virtual Meeting 2021 to Include Updated Poziotinib Twice Daily Dosing Data

Spectrum Pharmaceuticals Presentations at the Upcoming AACR Virtual Meeting 2021 to Include Updated Poziotinib Twice Daily Dosing Data

Castor Maritime Inc

CEL-SCI

Marathon Oil

cbdMD Inc

Reddit stocks always make noise across social media platforms. But these investments have serious catalysts connected to them.

7 Reddit Stocks With Upcoming Catalysts To Watch

Spectrum Pharmaceuticals, Inc.'s (SPPI) CEO Joe Turgeon on Q4 2020 Results - Earnings Call Transcript

HENDERSON, Nev.--(BUSINESS WIRE)---- $SPPI #earnings--Spectrum Pharmaceuticals Reports Fourth Quarter 2020 and Full Year 2020 Financial Results and Pipeline Update

Spectrum Pharmaceuticals Reports Fourth Quarter 2020 and Full Year 2020 Financial Results and Pipeline Update

HENDERSON, Nev.--(BUSINESS WIRE)---- $SPPI--Spectrum Pharmaceuticals to Report Fourth Quarter and Full Year 2020 Financial Results and Provide Corporate Update

Spectrum Pharmaceuticals to Report Fourth Quarter and Full Year 2020 Financial Results and Provide Corporate Update

HENDERSON, Nev.--(BUSINESS WIRE)---- $SPPI--Spectrum Pharmaceuticals Provides Update on ROLONTIS® (eflapegrastim) Pre-Approval Inspection

Spectrum Pharmaceuticals Provides Update on ROLONTIS® (eflapegrastim) Pre-Approval Inspection

The FDA grants a Fast Track designation to Spectrum Pharmaceuticals' (SPPI) poziotinib for treating non-small cell lung cancer in previously treated patients with HER2 exon 20 mutations.

Spectrum's (SPPI) NSCLC Drug Gets FDA's Fast Track Designation

Athenex

Bellus Health Inc

Catalyst Pharmaceuticals

New Age Beverages

OPKO Health

Uranium Energy

These penny stocks have more than just a low price point. They have Wall Street analysts backing up those prices with high price targets.

News for Spectrum Pharma Stock (SPPI)